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We describe the presentation, treatment, clinical outcome, and targeted genome analysis of a metastatic salivary acinic cell
carcinoma (AciCC). A 71-year-old male presented with a 3 cm right tail of a parotid lesion, first detected as a nodule by the
patient seven months earlier. He had a right total parotidectomy with cranial nerve VII resection, right facial nerve resection
and grafting, resection of the right conchal cartilage, and right modified radical neck dissection. The primary tumor revealed
AciCC with two distinct areas: a well-differentiated component with glandular architecture and a dedifferentiated component with
infiltrative growth pattern associated with prominent stromal response, necrosis, perineural invasion, and cellular pleomorphism.
Tumor staging was pT4 N0MX. Immunohistochemistry staining showed pankeratin (+), CD56 (−), and a Ki67 proliferation index
of 15%. Uponmicroscopic inspection, 49 local lymph nodes resected during parotidectomy were negative for cancer cells. Targeted
sequencing of the primary tumor revealed deletions ofCDKN2AandCDKN2B, a nonsensemutation inARID2, and singlemissense
mutations of unknown significance in nine other genes. Despite postoperative localized radiation treatment, follow-up whole body
PET/CT scan showed lung, soft tissue, bone, and livermetastases.Thepatient expired 9months after resection of the primary tumor.
1. Introduction
The incidence of salivary gland cancers is approximately 0.6%
of the incidence rate of all cancers in the United States [1, 2]
and acinic cell carcinomas (AciCCs) account for approxi-
mately 2.4% of salivary gland cancers [3]. Most salivary gland
AciCCs (86.3%) arise in the parotid gland and, to a much
lesser extent, in the submandibular gland, other major and
minor salivary glands, the parapharyngeal space, and the sub-
lingual gland [4, 5]. The median age of AciCC presentation is
52 years with 59% incidence in women and 41% incidence in
men [5]. Histologically, most tumors tend to be of low grade;
however, on occasion, poorly differentiated and high grade
tumors occur. The mainstay of treatment entails surgery
followed by postoperative radiation [6]. Chemotherapy is
generally not considered an effective treatment.The five-year
disease-specific survival rate of AciCC is 91% with worse
prognosis in cases where there is high grade histology, an
age at presentation of greater than 30 years, and evidence
for metastatic disease [5]. Local recurrences and distant
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metastases occur frequently, with most metastases occurring
in the lungs and bone and, to a lesser extent, in the central
nervous system, mediastinum, and liver [7]. In the single
previousmutational spectrum report of a patient with AciCC
whole exome analysis revealed deletions in CDKN2A,MTAP,
and PPP1R13B along with somatic nonsynonymous point
mutations in 14 other genes [8].
We reviewed the medical records and targeted genomic
profile of a male who presented with AciCC of the parotid
gland. Histopathology and immunohistochemistry were per-
formed at Kaiser Permanente, CA. The patient underwent
right total parotidectomy with cranial nerve VII resection,
right facial nerve resection and grafting, resection of the right
conchal cartilage, and right modified radical neck dissection.
Because AciCC of the parotid gland is typically recognized as
a low grade and indolent cancer, we sought to further study
the genetic profiling of this specific case due to its aggressive
clinical nature. Targeted genomic profiling of the parotid
tumor using clinical next generation sequencing (NGS) to a
minimum coverage depth of 500x was carried out on a Foun-
dationOne platform in a Clinical Laboratory Improvement
Amendments (CLIA) certified lab (Foundation Medicine,
Cambridge, MA) (Table S1 in Supplementary Material
available online at http://dx.doi.org/10.1155/2015/893694) [9].
FoundationOne uses targeted next generation sequencing to
interrogate the coding regions of 315 cancer related genes
and the introns of 28 genes that are reportedly involved in
structural rearrangements (Tables S2 and S3).
2. Case Report
2.1. Case History. We describe a 71-year-old male who pre-
sentedwith a 2 cm indurated nontender subcutaneous nodule
over the right angle of mandible with no redness, warmth,
or drainage. According to the patient, the nodule appeared
one month earlier and decreased in mass upon eating. His
previousmedical history was essential hypertension, primary
open angle glaucoma, and chronic kidney disease stage 3.
One month after presentation, needle aspiration of mass at
right tail of the parotid revealed a salivary gland neoplasm.
MRI revealed a 2.4 cm anterior-posterior × 2.4 cm transverse
× 2.6 cm cranial caudal septated cystic mass in the right
parotid lobe. A second fine needle aspiration performed four
months after presentation revealed another 1 cm approximate
diameter growing mass within the parotid. Five months
after presentation, just prior to scheduled surgery, pathology
analyses of computed tomography-guided biopsy results were
consistent with high grade AciCC. The patient’s presurgical
cancer workup included complete blood count, coagulation
panel, chemistry profile-20, and chest radiographs that were
all negative for metastatic cancer.
The patient underwent a right total parotidectomy with
cranial nerve VII resection, right facial nerve resection and
grafting, resection of the right conchal cartilage, and right
modified radical neck dissection. Intraoperatively, the tumor
was noted to encase the right facial nerve and extend to
ulcerated overlying skin. The face was rehabilitated with a
right AlloDerm facial sling and placement of right upper
eyelid gold weight. The facial defect was reconstructed with
a cervicofacial advancement flap. Pathology analysis revealed
a 3.0 × 3.0 × 3.0 cm AciCC with two distinct areas: a well-
differentiated component with glandular architecture and a
dedifferentiated component with infiltrative growth pattern
associated with prominent stromal response, necrosis, per-
ineural invasion, and cellular pleomorphism (Figure 1). At
the time of resection, the staging was pT4, N0,MX. Immuno-
histochemistry staining showed pankeratin (+), CD56 (−),
and a proliferation index of ∼15% based on Ki67.The surgical
margins were clear with the closest showing tumor 0.2 cm
from anterior inked margin.
Postoperatively, the patient received 6000 cGy in 30 frac-
tions using intensity modulated radiation therapy (IMRT)
to the parotid bed and right neck. Three months after
completing IMRT, a whole body PET/CT scan revealed mul-
tiple fluorodeoxyglucose- (FDG-) avid pulmonary nodules,
a 2.3 cm mass in the right infrahilar region with a maximum
standardized uptake value (SUV) of 5.74, a 2× 2.6 cm subcari-
nal lymph node (SUV 6.08), multiple FDG-avid liver lesions,
a soft tissue lesion in the lateral left upper quadrant 3× 2.7 cm,
and osseous metastases to the tenth thoracic vertebrae (T10)
(maximum SUV 8.4) and proximal right femur (Figure 2).
The patient developed dermal metastases along the neck
incision site. A CT-guided biopsy of a pulmonary nodule
confirmed metastatic AciCC with immunohistochemistry
negative for thyroid transcription factor-1 (TTF-1), cytoker-
atin 7 (CK7), and cytokeratin 20 (CK20).
Thepatient underwent palliative radiotherapy to a painful
left calcaneal bone metastasis and right femur metastasis. He
was placed on zoledronic acid for the osseous metastasis. He
was seen by medical oncology to discuss systemic treatment
options, but the patient declined the treatment. He was
ultimately placed on hospice due to progressive metastatic
disease and worsening functional status.
2.2. Genomic Profiling. The NGS analysis reported deletions
of two tumor suppressor genes on chromosome 9p21 that
encode three tumor suppressor proteins and a nonsense
mutation in another tumor suppressor gene on chromosome
12q12 (Table 1). One tumor suppressor gene is CDKN2B
(cyclin-dependent kinase inhibitor 2B), which encodes
p15INK4B [10–13] (Figure 3). The second tumor suppressor
gene is CDKN2A, which encodes two proteins, p16INK4A
and p14ARF. p16INK4A and p15INK4B are CDK inhibitors that
separately form complexes with cyclin-dependent kinase 4
(CDK4) and cyclin-dependent kinase 6 (CDK6) to inhibit
their interaction with cyclin D.These CDK inhibitors induce
cell cycle arrest at G1 checkpoints, preventing phosphory-
lation of retinoblastoma protein (Rb), thus halting the cell
cycle. p14ARF is created from a unique splicing event and
uses alternative reading frame in exons 2 and 3 of CDKN2A.
p14ARF stabilizes the tumor suppressor p53 by inhibiting its
negative regulatorMDM2. Deletion of CDKN2A leads to loss
of p14ARF, which causes abrogation of p53-dependent cell
cycle arrest, apoptosis, and other tumor suppressor functions
[14, 15].
Another tumor suppressor gene mutated in the patient’s
AciCC was AT-Rich Interactive Domain 2 (ARID2), which




Figure 1: Acinic cell carcinoma of the parotid gland. (a) The tumor exhibits two distinct areas on histologic examination. The two areas
are juxtaposed to each other and there is no evidence of transition. On the left, the well-differentiated area shows glandular architecture
and the area on the right side of the image shows an infiltrative growth pattern associated with prominent stromal response. H&E, 10x. (b)
Higher magnification of the well-differentiated area demonstrates polygonal cells without significant cytologic atypia, variably basophilic
granular cytoplasm, minimal pleomorphism, and inconspicuous mitotic activity. H&E, 40x. (c) Dedifferentiated regions of the tumor show
focal necrosis (arrowhead) and multiple foci of perineural invasion (star) H&E, 10x. (d) Cytologically, the dedifferentiated areas display more
pronounced pleomorphism and increased mitotic activity (arrowhead) H&E, 40x.
(a) (b) (c)
Figure 2:Widespreadmetastatic acinic cell carcinoma by positron-emission tomography/computed tomography (PET/CT). (a)Whole body
PET images demonstrate FDG-avid lesion in the lungs, liver, and bones. (b) Multiple metastatic pulmonary lesions were seen on noncontrast
chest CT. (c) Fused PET/CT images demonstrate multiple FDG-avid hepatic metastases.

























Figure 3: The CDKN2A-CDKN2B locus regulates the cell cycle. Genomic organization of the 9p21 locus containing CDKN2B encoding
p15INK4B and CDKN2A encoding p14ARF and p16INK4A. p14ARF is coded by exons E1𝛽, E2, and E3 and p16INK4A is coded by exons E1𝛼, E2,
and E3. E2 and E3 are shared by p14ARF and p16INK4A, but they use alternate reading frames to produce unique protein sequences. p15INK4B
and p16INK4A induce cell cycle arrest by complexing to CDK4 and CDK6 and preventing their complex formation with cyclin D. Rb remains
active (dephosphorylated) and prevents E2F-mediated transcription of target genes necessary for cell cycle progression from G1 to S phase.
p14ARF inhibits cell cycle progression and activates apoptosis by inhibiting MDM2, which leads to activation of p53.
Table 1: Somatic genomic alterations.
Gene Chr Coding change Base change Pathway
CDKN2A 9 Loss Loss Cyclin-dependent kinase inhibitor, Rb tumor suppressor
CDKN2B 9 Loss Loss Cyclin-dependent kinase inhibitor, Rb and p53 tumor suppressors
ARID2 12 E267∗ 799G>T Chromatin remodeling, tumor suppressor
AXL 19 T112M 335C>T Receptor tyrosine kinase signaling
ESR1 6 G90R 268G>C Transcription factor
FBXW7 4 E192A 575A>C Phosphorylation-dependent ubiquitination
GNA13 17 T365S 1093A>T G-protein signaling
KEAP1 19 C624Y 1871G>C Sensor of oxidative stress
KLHL6 3 S497T 1490G>C Receptor signaling
LRP1B 2 N1724Y 5170A>T Receptor-mediated endocytosis signaling
PLCG2 16 F528C 1583T>G Transmembrane signaling enzyme
PRSS8 16 A209T 625G>A Proteolytic enzymes
encodes AT-Rich Interactive Domain 2 protein (ARID2 pro-
tein), also known as BRG1-associated factor 200 (BAF200).
ARID2 protein is a subunit of the polybromo- and BRG1-
associated factor chromatin remodeling complex (PBAF) and
appears to be necessary for complex stability [16]. In general,
PBAF is responsible for nuclear receptor ligand-dependent
transcriptional activation and is part of the SWI/SNF family
of chromosome remodeling proteins [17]. A lack of ARID2
protein alters cellular transcription response to 𝛼-interferon
[16] and inhibits osteoblast differentiation [18]. ARID2 pro-
tein has four domains: AT-rich interaction domain (ARID),
RFX-like DNA bindingmotif (RFX), proline- and glutamine-
rich region (GLN), and two C-terminal C2H2 zinc finger
motifs (ZN) [19] (Figure 4). The patient harbored a loss-
of-function (LoF) nonsense E267∗ mutation resulting in a
truncated protein deficient in the RFX, GLN, and ZN.
Nine missense mutations of unknown significance in
AciCC were identified in AXL, ESR1, FBXW7, GNA13,
KEAP1, KLHL6, LRP1B, PLCG2, and PRSS8 (Table 1). Other
mutations in these nine genes have been reported in many
cancer types underscoring the need for functional genomics
to ascertain the significance of these particular changes in
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14-101 1634–1690 1835 aa523–582 793–1128
Figure 4: The protein domain arrangement in ARID2 protein. ARID2 has four discrete domains: the ARID domain (residues 14–101), the
RFX domain (residues 523–582), the GLN domain (residues 793–1128), and a domain that contains two ZnFs (1634–1690). The red arrow
indicates the approximate location of the E267∗ nonsense mutation identified in the AciCC of the patient.
AciCC [20]. Interestingly, 9 of the 12 documented genomic
insults are in genes involved in signaling pathways or reg-
ulation of the cell cycle (Table 1). Of the 10 point mutations
observed in the sample, 8 were transversions.
3. Discussion
The case presented herein is of a highly aggressive AciCC
in which both local recurrence and distant metastatic dis-
ease occurred within six months of curative intent surgery
and adjuvant radiotherapy. Histologically, the presence of
dedifferentiationwas a poor prognostic feature. Furthermore,
we detected two components juxtaposed to one another;
one is well-differentiated with glandular architecture and the
second shows infiltrative growth pattern associated with stro-
mal response. The second area has dedifferentiated regions
with focal necrosis, multiple foci of perineural invasion, pro-
nounced pleomorphism, and increasedmitotic activity. Inter-
estingly, the juxtaposition of the two areas is a feature found in
a subset of AciCC (𝑛 = 25) that failed to respond to extensive
resection and adjuvant therapy [21]. In this subset, local
recurrence or distant metastasis occurred in most patients
with 72.7% dead with disease with a mean of 2.9 years.
In addition, targeted next generation sequencing revealed
loss of tumor suppressor genes, CDKN2A, CDKN2B, and
ARID2, as well as several mutations in genes involved in cell
signaling, ubiquitination, cell cycle regulation, and endocy-
tosis. The presence of the multitude of genetic alterations
underscores the high grade, poorly differentiated nature of
the tumor and, conversely, may help to explain its highly
aggressive nature. Of course, because of the targeted nature
of this analysis, it is quite possible that there are mutations in
other critical genes not analyzed.
A single other report has been published where extensive
genetic analysis of a salivary gland AciCC primary tumor
was conducted [8]. In that report, whole exome sequencing
analysis was performed. A comparison with our targeted
sequencing studymay shed light on features shared in the two
cases. It was reported that a 58-year-old woman presented
with a right parotid mass consistent with Warthin’s tumor.
An initial CT scan revealed a right parotid mass. A year
later, another CT scan showed a mass centered in the right
parotid effacing the jugular vein and abutting the mandible
and skull base with extension along the facial nerve to the
geniculate ganglion. Pathologic examination revealed a low
grade AciCC with extensive perineural and lymphovascular
spread and the lymph nodes negative for malignancy. In
some respects, this contrasts with our patient who had a high
grade AciCC and developed multiple metastases. However,
similar to the previous case, the lymph nodes of our patient
were negative.The previous case study reported that 35 genes
were identified with somatic copy number aberrations and 14
with somatic single nucleotide variations. Somatic deletion of
CDKN2A was the only genomic aberration detected in both
patients, although we must consider that in our study only a
fraction of the exome was analyzed.
In both salivary gland AciCC tumors, the CDK4/6/Rb
and p53 pathways were targeted. It is worth noting that
deletion of CDKN2A is a frequent event in heat and neck
tumors. In one report, 22% of head and neck tumors (𝑛 =
279) have a deletion inCDKN2A [22].Of the 27 active clinical
trials underway for CDK4/6 inhibitors, four are specific for
solid tumors with CDK4/6 pathway activation [23]. The
FDA recently approved the CDK4/6 inhibitor palbociclib for
treatment of metastatic breast cancer in combination with
the aromatase inhibitor, letrozole [24]. In cancers that have
genomic driver insults in CDKN2A or CDKN2B, inhibition
of CDK4/6 is likely to be a therapeutic option worth investi-
gating.
The other clinical target relevant to this study is MDM2
[25]. MDM2 binds to the p53 transactivation domain and
mediates polyubiquitination of p53, leading to p53 proteol-
ysis by the 26S proteasome [26]. Seven drugs that prevent
complex formation between MDM2 and p53 are in phase
I clinical trials. Because the drugs will also likely activate
p53 in normal cells, it is expected that some side effects
will occur. Indeed, early results from clinical trials show that
two MDM2 targeting drugs cause thrombocytopenia and
one drug causes apoptosis of megakaryocyte progenitor cells
[25, 27, 28]. Other approaches to identify MDM2 inhibitors
without severe side effects are being explored [29].
This case study is the first report of the ARID2 nonsense
mutation (E267∗) in AciCC. Two other cases with this
specific genomic insult (AA E267∗; nuc c799G>T) have been
reported in hepatocellular carcinoma [30, 31]. A recent study
revealed that 18.2% of patients with HCV-associated hepa-
tocellular carcinoma have inactivating mutations in ARID2
[32]. ARID2 mutations have also been reported in pancre-
atic cancer, colorectal cancer, melanoma, and non-small-
cell lung cancer [32–42]. Furthermore, in 60 hepatocellular
samples evaluated by whole exome or genome sequencing,
35% harbored alterations in chromatin remodeling genes,
including ARID1, another member of the ARID superfamily
[32]. A study identified ARID2 loss-of-function mutations in
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5% of non-small-cell lung cancers, making it the 6th most
frequently mutated genes in this cancer type after TP53,
KRAS, EGFR, CDKN2A, and STK11 [35].
In our AciCC case, we also observed missense mutations
in AXL, ESR1, FBXW7, KEAP1, KLHL6, GNA13, PLCG2, and
LRP1B. Mutations in these genes have been reported in non-
head and neck cancers [30, 31]. AXL has been implicated
in epithelial-mesenchymal transition (EMT) and has been
hypothesized to play a key role not only in development of
metastasis, but also in resistance to chemotherapy and tar-
geted therapies, including lapatinib resistance in HER2-posi-
tive breast cancer [43] and in erlotinib resistance in EGFR-
mutant non-small-cell lung cancer [44]. Among other
salivary gland neoplasms, genomic alterations in FBXW7,
KLHL6, and LRP1B have been identified in adenoid cystic
carcinoma [33, 45]. Alterations of the oxidative stress gene
KEAP1 was reported in human papilloma virus negative
head-and-neck squamous cell carcinomas (HNSCCs) (5%)
[46].
FBXW7 codes for F-box and WD40 repeat domain con-
taining 7 protein (Fbxw7), a substrate recognition component
of the SCF (Skp1-Cul1-F-box protein) type ubiquitin ligase
complex. Fbxw7 plays a critical role in cell division, growth
and differentiation by binding to proto-oncoproteins (c-Myc,
Notch1, Notch4, c-Jun, cyclin E, KLF5, and mTOR) [47]. The
binding domain within Fbxw7 is a conserved phosphory-
lated domain known as the Cdc4 phosphodegron and leads
to ubiquitin-dependent proteolysis of the above proto-onco-
proteins. Since most of its substrates are growth-promoting,
Fbxw7 is thought of as a tumor suppressor. Overall, approx-
imately 6% of multiple samples from 15 different human
tumor types surveyed harbor FBXW7 mutations [48]. Most
of these mutations result in amino-acid substitutions at key
positions in theWD40 repeats with consequential disruption
of substrate binding. Hot spot mutations were observed in
the third WD40 repeat (nucleotides 1,393, 1,394 and 1,436).
The remaining mutations were either nonsense mutations
or mutations of unknown significance. The tumor in our
case study harbored one of these mutations of unknown
significance, E192A. A fibrolamellar HCC patient harboring
the same mutation was treated with vorinostat and sirolimus
as part of a phase I clinical trial formTOR inhibitors.The time
to treatment failure was 6.8+months [49].Thirty-one percent
of T cell acute lymphocytic leukemia (T-ALL) patients have
FBXW7 mutations with one reported case harboring the
E192A mutation [50].
In this report, targeted next generation sequencing was
performed on the excised primary parotid tumor. Recently,
researchers used whole genome sequencing data to develop
and validate “mutant-allele tumor heterogeneity” (MATH) as
a measure of intratumor heterogeneity in HNSCC suggesting
that it should be considered as a biomarker for survival in
these cancers [51]. Given that high intratumor heterogeneity
leads to worse clinical outcomes, one limitation of this study
is that repeated sampling of the tumor with whole exome
sequencing was not performed.
Recent cancer sequencing studies have unleashed an ever-
expanding catalog of somatic aberrations, involving novel
genes and pathways inmany cases [46, 52–56].This extensive
mutational heterogeneity can inform genome forward treat-
ment algorithms. This case study underscores the need to
sequence more AciCC samples multiple times for the geno-
mic, transcriptome, epigenomic, and proteomic annotation
of molecular alterations. Such information will deepen our
understanding of the pathophysiology, risk stratification,
prognosis of AciCC, and guide precision genome forward
treatment.
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